APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Amyotrophic Lateral Sclerosis (ALS)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Amyotrophic Lateral Sclerosis (ALS) Market Outlook and Growth Opportunities 2026

Report ID 173963210420 December 2025192 pages

Choose your research edition.

Industry ResearchAmyotrophic Lateral Sclerosis (ALS) Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Amyotrophic Lateral Sclerosis (ALS) Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Amyotrophic Lateral Sclerosis (ALS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Amyotrophic Lateral Sclerosis (ALS) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Amyotrophic Lateral Sclerosis (ALS) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Amyotrophic Lateral Sclerosis (ALS) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Amyotrophic Lateral Sclerosis (ALS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Amyotrophic Lateral Sclerosis (ALS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Amyotrophic Lateral Sclerosis (ALS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Amyotrophic Lateral Sclerosis (ALS) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Amyotrophic Lateral Sclerosis (ALS) market include Sun Pharma, Sanofi, Lunan Pharma, Mylan Pharma, Mitsubishi Tanabe Pharma, Glemark Generics, Covis Pharma and Apotex, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Amyotrophic Lateral Sclerosis (ALS) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Amyotrophic Lateral Sclerosis (ALS) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Amyotrophic Lateral Sclerosis (ALS) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Amyotrophic Lateral Sclerosis (ALS) market size, projected growth trends, production technologies, key applications, and end-use industries.

Amyotrophic Lateral Sclerosis (ALS) Segment by Company

Sun Pharma

Sanofi

Lunan Pharma

Mylan Pharma

Mitsubishi Tanabe Pharma

Glemark Generics

Covis Pharma

Apotex

Amyotrophic Lateral Sclerosis (ALS) Segment by Type

Riluzole

Edaravone (Radicava)

Other

Amyotrophic Lateral Sclerosis (ALS) Segment by Application

Hospital

Drugs Store

Other

Amyotrophic Lateral Sclerosis (ALS) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Amyotrophic Lateral Sclerosis (ALS) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Amyotrophic Lateral Sclerosis (ALS) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Amyotrophic Lateral Sclerosis (ALS) significant trends, drivers, influence factors in global and regions.

6. To analyze Amyotrophic Lateral Sclerosis (ALS) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Amyotrophic Lateral Sclerosis (ALS) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Amyotrophic Lateral Sclerosis (ALS) industry.

Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Amyotrophic Lateral Sclerosis (ALS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Amyotrophic Lateral Sclerosis (ALS) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Amyotrophic Lateral Sclerosis (ALS) Industry Trends Table 2. Amyotrophic Lateral Sclerosis (ALS) Industry Drivers Table 3. Amyotrophic Lateral Sclerosis (ALS) Industry Opportunities and Challenges Table 4. Amyotrophic Lateral Sclerosis (ALS) Industry Restraints Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Company (2021-2026) Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Company (k units) & (2021-2026) Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume Share by Company (2021-2026) Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Average Price (US$/unit) of Company (2021-2026) Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Amyotrophic Lateral Sclerosis (ALS) Key Company Manufacturing Base & Headquarters Table 12. Global Amyotrophic Lateral Sclerosis (ALS) Company, Product Type & Application Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Amyotrophic Lateral Sclerosis (ALS) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Riluzole Table 18. Significant Companies of Edaravone (Radicava) Table 19. Significant Companies of Other Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Type (2021-2026) & (k units) Table 22. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Type (2027-2032) & (k units) Table 23. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume Share by Type (2021-2026) Table 24. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume Share by Type (2027-2032) Table 25. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type (2021-2026) Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Drugs Store Table 32. Significant Companies of Other Table 33. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Application (2021-2026) & (k units) Table 35. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Application (2027-2032) & (k units) Table 36. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume Share by Application (2021-2026) Table 37. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume Share by Application (2027-2032) Table 38. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application (2021-2026) Table 42. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application (2027-2032) Table 43. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2021-2026) & (k units) Table 45. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2021-2026) Table 46. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2027-2032) & (k units) Table 47. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2027-2032) Table 48. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Region (2021-2026) Table 51. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Region (2027-2032) Table 53. Global Amyotrophic Lateral Sclerosis (ALS) Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Amyotrophic Lateral Sclerosis (ALS) Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 58. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2026) Table 59. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 60. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2027-2032) Table 61. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Market Share by Country (2021-2026) Table 63. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Market Share by Country (2027-2032) Table 65. Sun Pharma Company Information Table 66. Sun Pharma Business Overview Table 67. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 69. Sun Pharma Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 74. Sanofi Recent Development Table 75. Lunan Pharma Company Information Table 76. Lunan Pharma Business Overview Table 77. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 79. Lunan Pharma Recent Development Table 80. Mylan Pharma Company Information Table 81. Mylan Pharma Business Overview Table 82. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 84. Mylan Pharma Recent Development Table 85. Mitsubishi Tanabe Pharma Company Information Table 86. Mitsubishi Tanabe Pharma Business Overview Table 87. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 89. Mitsubishi Tanabe Pharma Recent Development Table 90. Glemark Generics Company Information Table 91. Glemark Generics Business Overview Table 92. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 94. Glemark Generics Recent Development Table 95. Covis Pharma Company Information Table 96. Covis Pharma Business Overview Table 97. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 99. Covis Pharma Recent Development Table 100. Apotex Company Information Table 101. Apotex Business Overview Table 102. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 104. Apotex Recent Development Table 105. Key Raw Materials Table 106. Raw Materials Key Suppliers Table 107. Amyotrophic Lateral Sclerosis (ALS) Distributors List Table 108. Amyotrophic Lateral Sclerosis (ALS) Customers List Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Amyotrophic Lateral Sclerosis (ALS) Product Image Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Amyotrophic Lateral Sclerosis (ALS) Sales (2021-2032) & (k units) Figure 5. Global Amyotrophic Lateral Sclerosis (ALS) Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Amyotrophic Lateral Sclerosis (ALS) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Riluzole Image Figure 10. Edaravone (Radicava) Image Figure 11. Other Image Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume Share by Type (2021-2032) Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Drugs Store Image Figure 20. Other Image Figure 21. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume Share by Application (2021-2032) Figure 24. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application (2021-2032) Figure 27. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Amyotrophic Lateral Sclerosis (ALS) Sales Value (2021-2032) & (US$ Million) Figure 32. North America Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Amyotrophic Lateral Sclerosis (ALS) Sales Value (2021-2032) & (US$ Million) Figure 38. South America Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Amyotrophic Lateral Sclerosis (ALS) Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Amyotrophic Lateral Sclerosis (ALS) Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Riluzole
  • Edaravone (Radicava)
  • Other
Applications
  • Hospital
  • Drugs Store
  • Other
Companies covered
  • Sun Pharma
  • Sanofi
  • Lunan Pharma
  • Mylan Pharma
  • Mitsubishi Tanabe Pharma
  • Glemark Generics
  • Covis Pharma
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value (2021-2032)
  4. 1.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume (2021-2032)
  5. 1.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Amyotrophic Lateral Sclerosis (ALS) Market Dynamics
  1. 2.1 Amyotrophic Lateral Sclerosis (ALS) Industry Trends
  2. 2.2 Amyotrophic Lateral Sclerosis (ALS) Industry Drivers
  3. 2.3 Amyotrophic Lateral Sclerosis (ALS) Industry Opportunities and Challenges
  4. 2.4 Amyotrophic Lateral Sclerosis (ALS) Industry Restraints
3 Amyotrophic Lateral Sclerosis (ALS) Market by Company
  1. 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Company Revenue Ranking in 2025
  2. 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Company (2021-2026)
  3. 3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Company (2021-2026)
  4. 3.4 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Company (2021-2026)
  5. 3.5 Global Amyotrophic Lateral Sclerosis (ALS) Company Ranking (2024-2026)
  6. 3.6 Global Amyotrophic Lateral Sclerosis (ALS) Company Manufacturing Base and Headquarters
  7. 3.7 Global Amyotrophic Lateral Sclerosis (ALS) Company Product Type and Application
  8. 3.8 Global Amyotrophic Lateral Sclerosis (ALS) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Amyotrophic Lateral Sclerosis (ALS) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Amyotrophic Lateral Sclerosis (ALS) Market by Type
  1. 4.1 Amyotrophic Lateral Sclerosis (ALS) Type Introduction
  2. 4.1.1 Riluzole
  3. 4.1.2 Edaravone (Radicava)
  4. 4.1.3 Other
  5. 4.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Type
  6. 4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Type
  10. 4.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Type (2021-2032)
  12. 4.3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type (2021-2032)
5 Amyotrophic Lateral Sclerosis (ALS) Market by Application
  1. 5.1 Amyotrophic Lateral Sclerosis (ALS) Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drugs Store
  4. 5.1.3 Other
  5. 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Application
  6. 5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Application
  10. 5.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application (2021-2032)
6 Amyotrophic Lateral Sclerosis (ALS) Regional Sales and Value Analysis
  1. 6.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2021-2032)
  3. 6.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2021-2026
  4. 6.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2027-2032)
  5. 6.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Region (2027-2032)
  9. 6.5 Global Amyotrophic Lateral Sclerosis (ALS) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Value (2021-2032)
  12. 6.6.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Value (2021-2032)
  15. 6.7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Amyotrophic Lateral Sclerosis (ALS) Sales Value (2021-2032)
  21. 6.9.2 South America Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Country, 2025 VS 2032
7 Amyotrophic Lateral Sclerosis (ALS) Country-level Sales and Value Analysis
  1. 7.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2032)
  4. 7.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026)
  5. 7.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032)
  6. 7.4 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Amyotrophic Lateral Sclerosis (ALS) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Amyotrophic Lateral Sclerosis (ALS) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sun Pharma
  2. 8.1.1 Sun Pharma Company Information
  3. 8.1.2 Sun Pharma Business Overview
  4. 8.1.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  6. 8.1.5 Sun Pharma Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Lunan Pharma
  14. 8.3.1 Lunan Pharma Company Information
  15. 8.3.2 Lunan Pharma Business Overview
  16. 8.3.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  18. 8.3.5 Lunan Pharma Recent Developments
  19. 8.4 Mylan Pharma
  20. 8.4.1 Mylan Pharma Company Information
  21. 8.4.2 Mylan Pharma Business Overview
  22. 8.4.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  24. 8.4.5 Mylan Pharma Recent Developments
  25. 8.5 Mitsubishi Tanabe Pharma
  26. 8.5.1 Mitsubishi Tanabe Pharma Company Information
  27. 8.5.2 Mitsubishi Tanabe Pharma Business Overview
  28. 8.5.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  30. 8.5.5 Mitsubishi Tanabe Pharma Recent Developments
  31. 8.6 Glemark Generics
  32. 8.6.1 Glemark Generics Company Information
  33. 8.6.2 Glemark Generics Business Overview
  34. 8.6.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  36. 8.6.5 Glemark Generics Recent Developments
  37. 8.7 Covis Pharma
  38. 8.7.1 Covis Pharma Company Information
  39. 8.7.2 Covis Pharma Business Overview
  40. 8.7.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  42. 8.7.5 Covis Pharma Recent Developments
  43. 8.8 Apotex
  44. 8.8.1 Apotex Company Information
  45. 8.8.2 Apotex Business Overview
  46. 8.8.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  48. 8.8.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Amyotrophic Lateral Sclerosis (ALS) Value Chain Analysis
  2. 9.1.1 Amyotrophic Lateral Sclerosis (ALS) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Amyotrophic Lateral Sclerosis (ALS) Sales Mode & Process
  6. 9.2 Amyotrophic Lateral Sclerosis (ALS) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
  9. 9.2.3 Amyotrophic Lateral Sclerosis (ALS) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst